Physician profile
Lee Roy Liskey
NPI 1609990993
$29,428.50
in general payments reported to CMS, 2019-2025
58 companies · $4,913 in 2025
The $4,913 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,256 · 2020: $3,499 · 2021: $3,654 · 2022: $3,630 · 2023: $5,987 · 2024: $4,490 · 2025: $4,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $1,800 · Education: $66.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,523.64 |
| Consulting Fee | $1,800.00 |
| Education | $66.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $6,610.10 | 2019-2025 | Dovato, Rukobia, Apretude |
| Gilead Sciences, INC. | $3,626.99 | 2019-2025 | Biktarvy |
| Theratechnologies INC. | $2,957.48 | 2019-2025 | Egrifta, Trogarzo |
| Emd Serono, INC. | $2,732.56 | 2019-2025 | Serostim, Serostim |
| Abbvie INC. | $2,043.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,248.73 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $867.12 | 2019-2023 | Symtuza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $678.19 | 2019-2024 | Xifaxan |
| Collegium Pharmaceutical, INC. | $587.17 | 2019-2024 | Belbuca |
| Lilly USA, LLC | $570.58 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Almatica Pharma LLC | $513.31 | 2023-2025 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $509.78 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $508.30 | 2022-2025 | Rexulti |
| Antares Pharma, INC. | $491.07 | 2019-2025 | Xyosted |
| Amarin Pharma, INC. | $469.43 | 2019-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Liskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.